Sequel Med Tech is an innovator in insulin delivery. According to the World Health Organization, there are over 79 million people in the world with Type 2 Diabetes who require insulin to control their blood sugar. Alan Lotvin, Co-Founder and CEO of Sequel; shares with us Sequel’s mission to reshape Diabetes care by improving insulin delivery methods.
Alan Lotvin, MD, Co-Founder & CEO, Sequel Med Tech
You must be logged in to rate.